Online inquiry

IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3448MR)

This product GTTS-WQ3448MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3448MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ279MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ5244MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CB-6
GTTS-WQ78MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ7805MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ14425MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ13001MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ5346MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ8936MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW